Sk Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, wh… Read more
Market Cap & Net Worth: Sk Biopharmaceuticals Co Ltd (326030)
Sk Biopharmaceuticals Co Ltd (KO:326030) has a market capitalization of $5.11 Billion (₩7.49 Trillion) as of March 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #5227 globally and #102 in its home market, demonstrating a -7.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sk Biopharmaceuticals Co Ltd's stock price ₩95600.00 by its total outstanding shares 78313250 (78.31 Million).
Sk Biopharmaceuticals Co Ltd Market Cap History: 2020 to 2026
Sk Biopharmaceuticals Co Ltd's market capitalization history from 2020 to 2026. Data shows change from $9.04 Billion to $5.11 Billion (-4.85% CAGR).
Sk Biopharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sk Biopharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Sk Biopharmaceuticals Co Ltd's market cap is 0.01 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.02x
Sk Biopharmaceuticals Co Ltd's market cap is 0.02 times its annual earnings
0.11x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $9.04 Billion | $26.00 Billion | -$247.41 Billion | 0.35x | N/A |
| 2021 | $5.20 Billion | $418.64 Billion | $64.85 Billion | 0.01x | 0.08x |
| 2022 | $3.86 Billion | $246.18 Billion | -$139.43 Billion | 0.02x | N/A |
| 2023 | $5.37 Billion | $354.89 Billion | -$32.88 Billion | 0.02x | N/A |
| 2024 | $5.94 Billion | $547.60 Billion | $240.74 Billion | 0.01x | 0.02x |
Competitor Companies of 326030 by Market Capitalization
Companies near Sk Biopharmaceuticals Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Sk Biopharmaceuticals Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Sk Biopharmaceuticals Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Sk Biopharmaceuticals Co Ltd's market cap moved from $9.04 Billion to $ 5.11 Billion, with a yearly change of -4.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩5.11 Billion | -23.27% |
| 2025 | ₩6.66 Billion | +12.15% |
| 2024 | ₩5.94 Billion | +10.66% |
| 2023 | ₩5.37 Billion | +39.25% |
| 2022 | ₩3.86 Billion | -25.82% |
| 2021 | ₩5.20 Billion | -42.49% |
| 2020 | ₩9.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Sk Biopharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.11 Billion USD |
| MoneyControl | $5.11 Billion USD |
| MarketWatch | $5.11 Billion USD |
| marketcap.company | $5.11 Billion USD |
| Reuters | $5.11 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.